Earnings

Here’s why Abbott Labs stock is getting dinged after a strong earnings beat

Products You May Like

Abbott Chairman of the Board and CEO Robert B. Ford delivers a keynote address at CES 2022 at The Venetian Las Vegas on January 6, 2022 in Las Vegas, Nevada.
Ethan Miller | Getty Images

Abbott Labs delivered a second-quarter earnings beat on Thursday, but the company’s ongoing litigation over its baby formula — plus softer guidance for the current quarter — is dragging down shares. We view the pullback as an opportunity.

Products You May Like

Articles You May Like

More young men are struggling financially. Here’s how that helped Trump win
Social Security beneficiaries to soon receive notices revealing the size of their 2025 benefit checks
AMC is poised to ride the box-office rebound, as long as its debt doesn’t get in the way
Gen Z, millennial retail investors are tapping into ETFs, report finds. Here are things to watch out for, expert say
Women prefer to play mobile games. China’s Tencent sees an opportunity

Leave a Reply

Your email address will not be published. Required fields are marked *